Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

there is a need for improving chemotherapy regimen for metastatic G3 NEC of GEP and Unknown origin and this goal may be achieved through more "personalized" chemotherapy regimen.the hypothesis is that mFOLFIRINOX regimen could be a good candidate for challenging the platinum-etoposide regimen in patients with metastatic G3 NEC of GEP or unknown origin. Furthermore, in order to get insights in the putative predictive biomarkers of efficacy of these two regimens, an effort toward a precise molecular characterization of these tumors is required in order to be able to define which subgroup of G3 NEC needs to be treated by which chemotherapy regimen. The FOLFIRINEC trial is set up in order to try to answer these questions

NCT Number	NCT04325425
Lead Sponsor	Centre Hospitalier Universitaire Dijon Collaborators: National Cancer Institute, France
Conditions	Neuroendocrine Carcinoma
Enrollment	218 participants
Start Date	2020-09-01
Primary Completion	2029-09 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2025-09-30